Last update Jan. 16, 2023
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Canrenoate Potassium is also known as
Canrenoate Potassium in other languages or writings:
Canrenoate Potassium belongs to this group or family:
Main tradenames from several countries containing Canrenoate Potassium in its composition:
|Tmax||0.5 ± 0.25||hours|
|T½||3.7 ± 1.2||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an aldosterone antagonist, potassium-sparing diuretic with actions and uses similar to those of spironolactone. Both are prodrugs that are metabolized to canrenone. It is used in the treatment of edema associated with heart failure or liver disease and in primary hyperaldosteronism. intravenous administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
The paucity of known pharmacokinetic data does not allow predictions about its possible excretion in breast milk.
The literature on this drug is scarce and it is sold in few countries.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.